Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Drugs for Non-small Cell Lung Cancer market report explains the definition, types, applications, major countries, and major players of the Drugs for Non-small Cell Lung Cancer market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Menarini
Amgen
Karyopharm Therapeutics
CytRx
Cornerstone Pharmaceuticals
CellAct Pharma
Ziopharm Oncology
Bristol-Myers Squibb
Cerulean Pharma
Kyowa Hakko Kirin
Alchemia
Genentech
Ligand Pharmaceuticals
Apotex
Intas Pharmaceuticals
Hospira
Cipla
Hikma Pharmaceuticals
Eli Lilly
Exelixis
GlaxoSmithKline
BioMarin Pharmaceutical
Fresenius Kabi
Sanofi
Curis
By Type:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
By End-User:
Hospitals
Clinics
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Drugs for Non-small Cell Lung Cancer Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Drugs for Non-small Cell Lung Cancer Outlook to 2028- Original Forecasts
-
2.2 Drugs for Non-small Cell Lung Cancer Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Drugs for Non-small Cell Lung Cancer Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Drugs for Non-small Cell Lung Cancer Market- Recent Developments
-
6.1 Drugs for Non-small Cell Lung Cancer Market News and Developments
-
6.2 Drugs for Non-small Cell Lung Cancer Market Deals Landscape
7 Drugs for Non-small Cell Lung Cancer Raw Materials and Cost Structure Analysis
-
7.1 Drugs for Non-small Cell Lung Cancer Key Raw Materials
-
7.2 Drugs for Non-small Cell Lung Cancer Price Trend of Key Raw Materials
-
7.3 Drugs for Non-small Cell Lung Cancer Key Suppliers of Raw Materials
-
7.4 Drugs for Non-small Cell Lung Cancer Market Concentration Rate of Raw Materials
-
7.5 Drugs for Non-small Cell Lung Cancer Cost Structure Analysis
-
7.5.1 Drugs for Non-small Cell Lung Cancer Raw Materials Analysis
-
7.5.2 Drugs for Non-small Cell Lung Cancer Labor Cost Analysis
-
7.5.3 Drugs for Non-small Cell Lung Cancer Manufacturing Expenses Analysis
8 Global Drugs for Non-small Cell Lung Cancer Import and Export Analysis (Top 10 Countries)
-
8.1 Global Drugs for Non-small Cell Lung Cancer Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Drugs for Non-small Cell Lung Cancer Export by Region (Top 10 Countries) (2017-2028)
9 Global Drugs for Non-small Cell Lung Cancer Market Outlook by Types and Applications to 2022
-
9.1 Global Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Radiofrequency Ablation (RFA) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Radiation Therapy Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Targeted Therapies Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Immunotherapy Consumption and Growth Rate (2017-2022)
-
9.2 Global Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Drugs for Non-small Cell Lung Cancer Market Analysis and Outlook till 2022
-
10.1 Global Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.2.2 Canada Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.2.3 Mexico Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.2 UK Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.3 Spain Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.4 Belgium Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.5 France Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.6 Italy Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.7 Denmark Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.8 Finland Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.9 Norway Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.10 Sweden Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.11 Poland Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.12 Russia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.3.13 Turkey Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.2 Japan Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.3 India Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.4 South Korea Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.5 Pakistan Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.6 Bangladesh Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.7 Indonesia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.8 Thailand Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.9 Singapore Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.10 Malaysia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.11 Philippines Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.4.12 Vietnam Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.2 Colombia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.3 Chile Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.4 Argentina Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.5 Venezuela Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.6 Peru Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.7 Puerto Rico Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.5.8 Ecuador Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6.2 Kuwait Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6.3 Oman Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6.4 Qatar Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6.5 Saudi Arabia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.6.6 United Arab Emirates Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.7.2 South Africa Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.7.3 Egypt Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.7.4 Algeria Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
-
10.8.2 New Zealand Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)
11 Global Drugs for Non-small Cell Lung Cancer Competitive Analysis
-
11.1 Menarini
-
11.1.1 Menarini Company Details
-
11.1.2 Menarini Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Menarini Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.1.4 Menarini Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Amgen
-
11.2.1 Amgen Company Details
-
11.2.2 Amgen Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Amgen Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.2.4 Amgen Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Karyopharm Therapeutics
-
11.3.1 Karyopharm Therapeutics Company Details
-
11.3.2 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.3.4 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 CytRx
-
11.4.1 CytRx Company Details
-
11.4.2 CytRx Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 CytRx Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.4.4 CytRx Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Cornerstone Pharmaceuticals
-
11.5.1 Cornerstone Pharmaceuticals Company Details
-
11.5.2 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.5.4 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 CellAct Pharma
-
11.6.1 CellAct Pharma Company Details
-
11.6.2 CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.6.4 CellAct Pharma Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Ziopharm Oncology
-
11.7.1 Ziopharm Oncology Company Details
-
11.7.2 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.7.4 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Bristol-Myers Squibb
-
11.8.1 Bristol-Myers Squibb Company Details
-
11.8.2 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.8.4 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Cerulean Pharma
-
11.9.1 Cerulean Pharma Company Details
-
11.9.2 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.9.4 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Kyowa Hakko Kirin
-
11.10.1 Kyowa Hakko Kirin Company Details
-
11.10.2 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.10.4 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Alchemia
-
11.11.1 Alchemia Company Details
-
11.11.2 Alchemia Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Alchemia Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.11.4 Alchemia Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Genentech
-
11.12.1 Genentech Company Details
-
11.12.2 Genentech Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Genentech Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.12.4 Genentech Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Ligand Pharmaceuticals
-
11.13.1 Ligand Pharmaceuticals Company Details
-
11.13.2 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.13.4 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Apotex
-
11.14.1 Apotex Company Details
-
11.14.2 Apotex Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Apotex Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.14.4 Apotex Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Intas Pharmaceuticals
-
11.15.1 Intas Pharmaceuticals Company Details
-
11.15.2 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.15.4 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Hospira
-
11.16.1 Hospira Company Details
-
11.16.2 Hospira Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Hospira Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.16.4 Hospira Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Cipla
-
11.17.1 Cipla Company Details
-
11.17.2 Cipla Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Cipla Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.17.4 Cipla Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 Hikma Pharmaceuticals
-
11.18.1 Hikma Pharmaceuticals Company Details
-
11.18.2 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.18.4 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Eli Lilly
-
11.19.1 Eli Lilly Company Details
-
11.19.2 Eli Lilly Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.19.4 Eli Lilly Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Exelixis
-
11.20.1 Exelixis Company Details
-
11.20.2 Exelixis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Exelixis Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.20.4 Exelixis Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 GlaxoSmithKline
-
11.21.1 GlaxoSmithKline Company Details
-
11.21.2 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.21.4 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 BioMarin Pharmaceutical
-
11.22.1 BioMarin Pharmaceutical Company Details
-
11.22.2 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.22.4 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.22.5 Recent Research and Development Strategies
-
11.23 Fresenius Kabi
-
11.23.1 Fresenius Kabi Company Details
-
11.23.2 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.23.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.23.4 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.23.5 Recent Research and Development Strategies
-
11.24 Sanofi
-
11.24.1 Sanofi Company Details
-
11.24.2 Sanofi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.24.3 Sanofi Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.24.4 Sanofi Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.24.5 Recent Research and Development Strategies
-
11.25 Curis
-
11.25.1 Curis Company Details
-
11.25.2 Curis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.25.3 Curis Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
11.25.4 Curis Drugs for Non-small Cell Lung Cancer Product Portfolio
-
11.25.5 Recent Research and Development Strategies
12 Global Drugs for Non-small Cell Lung Cancer Market Outlook by Types and Applications to 2028
-
12.1 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Radiofrequency Ablation (RFA) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Targeted Therapies Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Drugs for Non-small Cell Lung Cancer Market Analysis and Outlook to 2028
-
13.1 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.2.2 Canada Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.2.3 Mexico Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.2 UK Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.3 Spain Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.4 Belgium Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.5 France Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.6 Italy Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.7 Denmark Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.8 Finland Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.9 Norway Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.10 Sweden Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.11 Poland Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.12 Russia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.3.13 Turkey Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.2 Japan Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.3 India Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.4 South Korea Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.8 Thailand Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.9 Singapore Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.11 Philippines Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.2 Colombia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.3 Chile Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.4 Argentina Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.6 Peru Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6.3 Oman Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6.4 Qatar Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.7.2 South Africa Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.7.3 Egypt Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.7.4 Algeria Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Drugs for Non-small Cell Lung Cancer
-
Figure of Drugs for Non-small Cell Lung Cancer Picture
-
Table Global Drugs for Non-small Cell Lung Cancer Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Drugs for Non-small Cell Lung Cancer Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Radiofrequency Ablation (RFA) Consumption and Growth Rate (2017-2022)
-
Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Therapies Consumption and Growth Rate (2017-2022)
-
Figure Global Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Table North America Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure United States Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Canada Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Mexico Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table Europe Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure Germany Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure UK Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Spain Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Belgium Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure France Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Italy Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Denmark Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Finland Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Norway Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Sweden Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Poland Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Russia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Turkey Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table APAC Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure China Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Japan Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure India Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Korea Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Thailand Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Singapore Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Philippines Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table South America Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure Brazil Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Colombia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Chile Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Argentina Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Peru Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table GCC Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure Bahrain Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Oman Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Qatar Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table Africa Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure Nigeria Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Africa Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Egypt Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Algeria Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table Oceania Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)
-
Figure Australia Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Table Menarini Company Details
-
Table Menarini Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Menarini Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Menarini Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Amgen Company Details
-
Table Amgen Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Amgen Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Karyopharm Therapeutics Company Details
-
Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table CytRx Company Details
-
Table CytRx Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table CytRx Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table CytRx Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Cornerstone Pharmaceuticals Company Details
-
Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table CellAct Pharma Company Details
-
Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Ziopharm Oncology Company Details
-
Table Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Bristol-Myers Squibb Company Details
-
Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Cerulean Pharma Company Details
-
Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Kyowa Hakko Kirin Company Details
-
Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Alchemia Company Details
-
Table Alchemia Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alchemia Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Alchemia Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Genentech Company Details
-
Table Genentech Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Genentech Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Ligand Pharmaceuticals Company Details
-
Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Apotex Company Details
-
Table Apotex Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Apotex Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Apotex Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Intas Pharmaceuticals Company Details
-
Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Hospira Company Details
-
Table Hospira Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hospira Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Hospira Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Cipla Company Details
-
Table Cipla Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Cipla Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Hikma Pharmaceuticals Company Details
-
Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Eli Lilly Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Exelixis Company Details
-
Table Exelixis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Exelixis Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Exelixis Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table BioMarin Pharmaceutical Company Details
-
Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Fresenius Kabi Company Details
-
Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Sanofi Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Table Curis Company Details
-
Table Curis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Curis Drugs for Non-small Cell Lung Cancer Main Business and Markets Served
-
Table Curis Drugs for Non-small Cell Lung Cancer Product Portfolio
-
Figure Global Radiofrequency Ablation (RFA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Therapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Table North America Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure United States Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure Germany Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure China Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure Brazil Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)
-
Figure Australia Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
